Search Results - "Pezaro, C"

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) by Loriot, Y., Bianchini, D., Ileana, E., Sandhu, S., Patrikidou, A., Pezaro, C., Albiges, L., Attard, G., Fizazi, K., De Bono, J.S., Massard, C.

“…Androgen receptor (AR) signalling remains critically important in metastatic castration-resistant prostate cancer (mCRPC) as confirmed by recent phase III…”
Get full text

Prostate cancer: measuring PSA by Pezaro, C., Woo, H. H., Davis, I. D.

“…Population screening with prostate‐specific antigen (PSA) for detection of prostate cancer is a topic associated with ongoing dissent and confusion within the…”
Get full text

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone by Bianchini, D, Lorente, D, Rodriguez-Vida, A, Omlin, A, Pezaro, C, Ferraldeschi, R, Zivi, A, Attard, G, Chowdhury, S, de Bono, J.S

“…Abstract Background The new generation anti-androgen enzalutamide and the potent CYP17 inhibitor abiraterone have both demonstrated survival benefits in…”
Get full text

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? by Mezynski, J., Pezaro, C., Bianchini, D., Zivi, A., Sandhu, S., Thompson, E., Hunt, J., Sheridan, E., Baikady, B., Sarvadikar, A., Maier, G., Reid, A.H.M., Mulick Cassidy, A., Olmos, D., Attard, G., de Bono, J.

“…Abiraterone and docetaxel are both approved treatments for men with metastatic castration-resistant prostate cancer (mCRPC). Abiraterone pre-docetaxel is…”
Get full text

Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer by Omlin, A, J Pezaro, C, Zaidi, S, Lorente, D, Mukherji, D, Bianchini, D, Ferraldeschi, R, Sandhu, S, Dearnaley, D, Parker, C, Van As, N, de Bono, J S, Attard, G

“…Background: Abiraterone is a standard treatment for men with castration-resistant prostate cancer (CRPC). We evaluated the antitumour activity of abiraterone…”
Get full text

Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial by Annala, M., Fu, S., Bacon, J.V.W., Sipola, J., Iqbal, N., Ferrario, C., Ong, M., Wadhwa, D., Hotte, S.J., Lo, G., Tran, B., Wood, L.A., Gingerich, J.R., North, S.A., Pezaro, C.J., Ruether, J.D., Sridhar, S.S., Kallio, H.M.L., Khalaf, D.J., Wong, A., Beja, K., Schönlau, E., Taavitsainen, S., Nykter, M., Vandekerkhove, G., Azad, A.A., Wyatt, A.W., Chi, K.N.

“…Treatment of poor prognosis metastatic castration-resistant prostate cancer (mCRPC) includes taxane chemotherapy and androgen receptor pathway inhibitors…”
Get full text

Visceral Disease in Castration-resistant Prostate Cancer by Pezaro, Carmel J, Omlin, Aurelius, Lorente, David, Nava Rodrigues, Daniel, Ferraldeschi, Roberta, Bianchini, Diletta, Mukherji, Deborah, Riisnaes, Ruth, Altavilla, Amelia, Crespo, Mateus, Tunariu, Nina, de Bono, Johann S, Attard, Gerhardt

“…Abstract Metastatic involvement of the viscera in men with advanced castration-resistant prostate cancer (CRPC) has been poorly characterised to date. In 359…”
Get full text

Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone by Lorente, D, Omlin, A, Ferraldeschi, R, Pezaro, C, Perez, R, Mateo, J, Altavilla, A, Zafeirou, Z, Tunariu, N, Parker, C, Dearnaley, D, Gillessen, S, de Bono, J, Attard, G

“…Background: Abiraterone is a CYP17A1 inhibitor that improves survival in castration-resistant prostate cancer (CRPC). Abiraterone is licensed in combination…”
Get full text

Abiraterone and Novel Antiandrogens: Overcoming Castration Resistance in Prostate Cancer by Ferraldeschi, R, Pezaro, C, Karavasilis, V, de Bono, J

“…Suppression of gonadal androgens by medical or surgical castration remains the mainstay of treatment for patients with advanced prostate cancer. However, the…”
Get full text

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer by Leibowitz-Amit, R., Templeton, A.J., Omlin, A., Pezaro, C., Atenafu, E.G., Keizman, D., Vera-Badillo, F., Seah, J.-A., Attard, G., Knox, J.J., Sridhar, S.S., Tannock, I.F., de Bono, J.S., Joshua, A.M.

“…Abiraterone acetate (abiraterone) prolongs overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC). This study's…”
Get full text

First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer by Bianchini, D, Omlin, A, Pezaro, C, Lorente, D, Ferraldeschi, R, Mukherji, D, Crespo, M, Figueiredo, I, Miranda, S, Riisnaes, R, Zivi, A, Buchbinder, A, Rathkopf, D E, Attard, G, Scher, H I, de Bono, J, Danila, D C

“…Background: Prostate cancer remains dependent of androgen receptor (AR) signalling, even after emergence of castration resistance. EZN-4176 is a…”
Get full text

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone by Massard, C., Mateo, J., Loriot, Y., Pezaro, C., Albiges, L., Mehra, N., Varga, A., Bianchini, D., Ryan, C.J., Petrylak, D.P., Attard, G., Shen, L., Fizazi, K., de Bono, J.

“…Abiraterone and cabazitaxel improve survival in patients with metastatic castration-resistant prostate cancer (mCRPC). We conducted an open-label phase I/II…”
Get full text

Examining skeletal-related events in Australian men with castration-resistant prostate cancer (CRPC) by Anton, A., Wong, S., Parente, P., Azad, A., Shapiro, J.A., Weickhardt, A., Torres, J., Parnis, F., Goh, J., Semira, C., Gibbs, P., Tran, B., Pezaro, C.

Get full text

Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer by Pezaro, C, Mukherji, D, Tunariu, N, Cassidy, A M, Omlin, A, Bianchini, D, Seed, G, Reid, A H M, Olmos, D, de Bono, J S, Attard, G

“…Background: Standard medical castration reduces muscle mass. We sought to characterize body composition changes in men undergoing maximal androgen suppression…”
Get full text

A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC) by Chi, K.N., Taavitsainen, S., Iqbal, N., Ferrario, C., Ong, M., Wadhwa, D., Hotte, S.J., Lo, G., Tran, B., Azad, A., Wood, L., Gingerich, J.R., North, S., Pezaro, C.V., Ruether, D., Sridhar, S.S., Annala, M., Bacon, J., Wyatt, A.W.

Get full text

Platinum-based therapy in men with metastatic castration resistant prostate (mCRPC) with or without DNA repair defects: A multicentre retrospective analysis by Gillessen, S., Schmid, S., Beltran, H., Almeida, D.V.P., Mehra, N., Lavaud, P., Morales Barrera, R., Pignataro, D., Castro Marcos, E., Conteduca, V., Efstathiou, E., Le, H.M.L., Pezaro, C.V., Suzuki, H., Zivi, A., Klingbiel, D., Omlin, A.G.

Get full text

'First, do no harm': managing the metabolic impacts of androgen deprivation in men with advanced prostate cancer by Lomax, A. J., Parente, P., Gilfillan, C., Livingston, P. M., Davis, I. D., Pezaro, C.

“…Androgen deprivation therapy (ADT) is a standard systemic treatment for men with prostate cancer. Men on ADT may be elderly and have comorbidities that are…”
Get full text

2586 Pattern of presentation of brain metastases (BM) in metastatic renal cell cancer (mRCC) patients (pts) treated with targeted therapies (TT): Implications for screening practice by Spain, L, Dowling, A, Kwan, E, Pezaro, C, Dai, D, Chia, P, Tran, B, Pook, D, Weickhardt, A

Get full text

Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from ‘castration-resistant’ prostate cancer by Pezaro, C.J., Omlin, A., Mastris, K., Attard, G., Beer, T.M., Chi, K.N., Chowdhury, S., Davis, I.D., Drake, C.G., de Bono, J.S., Efstathiou, E., Gravis, G., Higano, C.S., Hussain, M., James, N., Logothetis, C.J., Morgans, A., Parker, C., Ryan, C.J., Saad, F., Sartor, O., Small, E.J., Sternberg, C.N., Sweeney, C.J., Tannock, I., Tombal, B., Gillessen, S.

Get full text

2579 Evaluation of clinical decision-making and the use of circulating tumor cells (CTCs) by physicians treating castration-resistant prostate cancer (CRPC) by Lorente, D, Ravi, P, Mehra, N, Gillman, A, Omlin, A, Pezaro, C, Miranda, M, Mateo, J, Rescigno, P, Kolinsky, M, Porta, N, Jayaram, A, Bianchini, D, Hall, E, Ijzerman, M.J, De Bono, J.S

Get full text